Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucocerebrosidase (GCase) is a lysosomal enzyme that catalyzes the hydrolysis of glucosylceramide into ceramide and glucose. It is encoded by the GBA1 gene. Deficiency in GCase activity leads to Gaucher disease and is also a risk factor for Parkinson's disease. Therapeutic strategies include enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).
Hydrolyzes glucosylceramide into ceramide and glucose.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glucocerebrosidase (GCase).